A DOUBLE-BLIND, CONTROLLED TRIAL OF NABILONE VS PROCHLORPERAZINE FOR REFRACTORY EMESIS INDUCED BY CANCER-CHEMOTHERAPY

被引：36

作者：

JOHANSSON, R ^{[1
]}

KILKKU, P ^{[1
]}

GROENROOS, M ^{[1
]}

机构：

[1] UNIV TURKU,CENT HOSP,DEPT OBSTET & GYNECOL,DIV ONCOL,SF-20500 TURKU 50,FINLAND

来源：

关键词：

D O I：

10.1016/S0305-7372(82)80032-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：25 / 33

页数：9

共 9 条

[1] EINHORN LH, 1981, J CLIN PHARMACOL, V21, P64
[2] 2-PERIOD CHANGE-OVER DESIGN AND ITS USE IN CLINICAL TRIALS
GRIZZLE, JE
[J]. BIOMETRICS, 1965, 21 (02) : 467 - &
[3] HERMAN TS, 1977, BIOMED EXPRESS, V27, P331
[4] LEMBERGER L, 1975, CLIN PHARMACOL THER, V18, P720
[5] MCCARTHY LE, 1977, PHARMACOLOGIST, V19, P233
[6] SUPPRESSION OF CARDIAC CONDITIONED-RESPONSE BY DELTA-9-TETRAHYDROCANNABINOL - COMPARISON WITH OTHER DRUGS
MCLENDON, DM
HARRIS, RT
MAULE, WF
[J]. PSYCHOPHARMACOLOGY, 1976, 50 (02) : 159 - 163
[7] ANTIEMETIC EFFECT OF DELTA-9-TETRAHYDROCANNABINOL IN PATIENTS RECEIVING CANCER CHEMOTHERAPY
SALLAN, SE
ZINBERG, NE
FREI, E
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1975, 293 (16) : 795 - 797
[8] STEELE N, 1980, CANCER TREAT REP, V64, P219
[9] SWEET DL, 1980, JAMA-J AM MED ASSOC, V243, P1265